Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907749200> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2907749200 endingPage "24" @default.
- W2907749200 startingPage "24" @default.
- W2907749200 abstract "Introduction: Tumor profiling tests can help to identify whether women with breast cancer need chemotherapy due to their risk of relapse, and some may be able to predict benefit from chemotherapy. We focused on four genetic tests: Oncotype DX (O-DX), MammaPrint (MMP), EndoPredict and Prosigna, and one immunohistochemistry test, IHC4, for the National Institute of Health and Care Excellence as part of their Diagnostic Appraisal Programme. Methods: A systematic review was undertaken, including searching of nine databases in February 2017 plus other sources including a previous review published in 2013. The review included studies assessing clinical effectiveness of the five tumor profiling tests, with or without clinicopathological factors, to guide decisions about adjuvant chemotherapy in people with ER-positive, HER-2 negative, Stage I-II cancer with 0 to 3 positive lymph nodes (LN). The PROBAST tool and Cochrane risk of bias tools were used to assess risk of bias. Results: A total of 153 studies were included; the strength of evidence base for individual tests was varied. Results suggest all tests are prognostic for risk of relapse, though results were more varied in LN positive (+) patients than in LN negative (0) patients. Evidence was limited about whether tests can predict benefit from chemotherapy (available for MMP and O-DX only). Studies that assessed the impact of the tests on clinical decisions indicate that the net change in chemotherapy recommendations or decisions pre-/post-test ranged from an increase of one percent to a decrease of 23 percent among UK studies, and a decrease of zero percent to 64 percent across European studies. Conclusions: The studies included in the review suggest that all of the tests can provide prognostic information on the risk of relapse; however results were more varied in LN+ patients than in LN0 patients. There is limited and varying evidence for prediction of chemotherapy benefit." @default.
- W2907749200 created "2019-01-11" @default.
- W2907749200 creator A5014159829 @default.
- W2907749200 creator A5015385670 @default.
- W2907749200 creator A5017096926 @default.
- W2907749200 creator A5020134464 @default.
- W2907749200 creator A5047242315 @default.
- W2907749200 creator A5049040242 @default.
- W2907749200 creator A5051630157 @default.
- W2907749200 creator A5055996064 @default.
- W2907749200 creator A5057977236 @default.
- W2907749200 creator A5061681421 @default.
- W2907749200 date "2018-01-01" @default.
- W2907749200 modified "2023-10-18" @default.
- W2907749200 title "OP66 Tumor Profiling Tests In Early Breast Cancer: A Systematic Review" @default.
- W2907749200 doi "https://doi.org/10.1017/s0266462318001095" @default.
- W2907749200 hasPublicationYear "2018" @default.
- W2907749200 type Work @default.
- W2907749200 sameAs 2907749200 @default.
- W2907749200 citedByCount "0" @default.
- W2907749200 crossrefType "journal-article" @default.
- W2907749200 hasAuthorship W2907749200A5014159829 @default.
- W2907749200 hasAuthorship W2907749200A5015385670 @default.
- W2907749200 hasAuthorship W2907749200A5017096926 @default.
- W2907749200 hasAuthorship W2907749200A5020134464 @default.
- W2907749200 hasAuthorship W2907749200A5047242315 @default.
- W2907749200 hasAuthorship W2907749200A5049040242 @default.
- W2907749200 hasAuthorship W2907749200A5051630157 @default.
- W2907749200 hasAuthorship W2907749200A5055996064 @default.
- W2907749200 hasAuthorship W2907749200A5057977236 @default.
- W2907749200 hasAuthorship W2907749200A5061681421 @default.
- W2907749200 hasConcept C121608353 @default.
- W2907749200 hasConcept C126322002 @default.
- W2907749200 hasConcept C143998085 @default.
- W2907749200 hasConcept C199360897 @default.
- W2907749200 hasConcept C2776694085 @default.
- W2907749200 hasConcept C2779256446 @default.
- W2907749200 hasConcept C29456083 @default.
- W2907749200 hasConcept C3018227240 @default.
- W2907749200 hasConcept C41008148 @default.
- W2907749200 hasConcept C530470458 @default.
- W2907749200 hasConcept C71924100 @default.
- W2907749200 hasConceptScore W2907749200C121608353 @default.
- W2907749200 hasConceptScore W2907749200C126322002 @default.
- W2907749200 hasConceptScore W2907749200C143998085 @default.
- W2907749200 hasConceptScore W2907749200C199360897 @default.
- W2907749200 hasConceptScore W2907749200C2776694085 @default.
- W2907749200 hasConceptScore W2907749200C2779256446 @default.
- W2907749200 hasConceptScore W2907749200C29456083 @default.
- W2907749200 hasConceptScore W2907749200C3018227240 @default.
- W2907749200 hasConceptScore W2907749200C41008148 @default.
- W2907749200 hasConceptScore W2907749200C530470458 @default.
- W2907749200 hasConceptScore W2907749200C71924100 @default.
- W2907749200 hasIssue "S1" @default.
- W2907749200 hasLocation W29077492001 @default.
- W2907749200 hasOpenAccess W2907749200 @default.
- W2907749200 hasPrimaryLocation W29077492001 @default.
- W2907749200 hasRelatedWork W2013809648 @default.
- W2907749200 hasRelatedWork W2020150632 @default.
- W2907749200 hasRelatedWork W2364515834 @default.
- W2907749200 hasRelatedWork W2369039771 @default.
- W2907749200 hasRelatedWork W2370076106 @default.
- W2907749200 hasRelatedWork W2379009234 @default.
- W2907749200 hasRelatedWork W2388730008 @default.
- W2907749200 hasRelatedWork W2586147948 @default.
- W2907749200 hasRelatedWork W2588049562 @default.
- W2907749200 hasRelatedWork W3166027310 @default.
- W2907749200 hasVolume "34" @default.
- W2907749200 isParatext "false" @default.
- W2907749200 isRetracted "false" @default.
- W2907749200 magId "2907749200" @default.
- W2907749200 workType "article" @default.